Videos
|
Genomic Evolution of Pirtobrutinib Resistance
Dr. Brown discusses her abstract on the genomic evolution of pirtobrutinib resistance at the 2023 European Hematology Association Congress in Frankfurt, Germany. |
|
The Use of Novel PI3K Inhibitors in CLL
Jennifer R. Brown, MD, PhD, reviews the data from the phase III DUO trial of duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia. |
|
ASH Impact Series, Treating High-Risk CLL
Jennifer Brown, MD, PhD, discusses combination strategies for high-risk CLL, compelling treatment approaches for achieving and maintaining negative minimal residual disease for patients with high-risk CLL, and more. Dr. Brown presented on the topic at the 2016 ASH Meeting on Hematologic Malignancies in a session titled “How I Treat CLL: High-Risk Genetics.” |
|
Presentation of Best CLL Abstract
in this presentation from the Lymphoma and Myeloma 2017, Dr. Jennifer R. Brown presents her award-winning CLL abstract. |
|
Safety Profiles of Idelalisib, Duvelisib, and TGR-1202 in treating CLL
Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, reviews the efficacy and safety profile of the PI3K delta inhibitor, idelalisib, in the treatment of chronic lymphocytic leukemia (CLL) noting that due to the difficulty in managing its toxicity profiles, the drug has limited to treating relapsed refractory CLL. Other drugs that are evaluated by Dr. Brown include the P13K gamma/delta inhibitor duvelisib, and the novel drug, TGR-1202. This video was recorded at the iwCLL 2017 in New York NY. |